Physician profile
Benjamin Moyer
NPI 1154950277
$3,761.46
in general payments reported to CMS, 2019-2025
41 companies · $1,549 in 2025
The $1,549 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.58 · 2023: $531 · 2024: $1,643 · 2025: $1,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,636.89 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.94 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $349.72 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $300.23 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $281.06 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $221.32 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $171.66 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.36 | 2023-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $141.88 | 2024-2025 | Rexulti |
| Pfizer INC. | $136.92 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.35 | 2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $114.49 | 2024-2025 | Quviviq, Quviviq |
| Amgen INC. | $111.24 | 2023-2025 | Evenity, Otezla, Repatha |
| Axsome Therapeutics, INC. | $111.07 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $100.10 | 2024-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $95.72 | 2023-2025 | Trintellix |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $75.15 | 2023-2025 | Inogen At Home Stationary Concentrator |
| Inspire Medical Systems, INC. | $60.49 | 2024-2025 | Inspire |
| Dexcom, INC. | $58.91 | 2023-2024 | Dexcom G6 Transmitter |
| Depuy Synthes Sales INC. | $56.14 | 2025 | Na |
| Smith+Nephew, INC. | $52.68 | 2024 | Real Intelligence |
| Boston Scientific Corporation | $52.31 | 2025 | Wavewriter Alpha Prime 16 |
| Neurocrine Biosciences, INC. | $49.90 | 2023-2024 | Ingrezza |
| Glaxosmithkline, LLC. | $44.23 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Goode Surgical INC | $39.58 | 2022 | |
| Phathom Pharmaceuticals, INC. | $37.73 | 2024-2025 | Voquezna |
| Tactile Systems Technology INC | $36.86 | 2025 | Flexitouch Plus, Nimbl |
| Alkermes, INC. | $35.03 | 2023-2024 | Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $34.09 | 2024-2025 | Eliquis, Camzyos |
| Antares Pharma, INC. | $29.97 | 2024-2025 | Xyosted |
| Paratek Pharmaceuticals, INC. | $29.20 | 2023-2024 | Nuzyra |
| Baxter Healthcare | $26.39 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Abbott Laboratories | $24.99 | 2025 | Freestyle Libre 3 |
| Lundbeck LLC | $23.64 | 2025 | Vyepti |
| Xeris Pharmaceuticals, INC. | $22.53 | 2024 | Gvoke Hypopen |
| Vanda Pharmaceuticals INC. | $21.33 | 2025 | Hetlioz, Fanapt |
| Medtronic, INC. | $20.78 | 2024 | Intellis Adaptivestim |
| Cequr Corporation | $18.74 | 2025 | Cequr Simplicity |
| Tonix Medicines, INC. | $17.45 | 2025 | Tonmya |
| Ibsa Pharma INC. | $16.92 | 2025 | Licart, Flector, Tirosint |
| Exact Sciences Corporation | $16.24 | 2025 | The Cologuard Plus Collection Kit |
| Nevro Corp. | $15.12 | 2023 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Moyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.